TY - JOUR
T1 - Efficient diagnosis for endoscopic remission in Crohn’s diseases by the combination of three non-invasive markers
AU - Takei, Kensuke
AU - Inokuchi, Toshihiro
AU - Hiraoka, Sakiko
AU - Ishiguro, Mikako
AU - Toyosawa, Junki
AU - Aoyama, Yuki
AU - Igawa, Shoko
AU - Takeuchi, Keiko
AU - Yamasaki, Yasushi
AU - Kinugasa, Hideaki
AU - Takahara, Masahiro
AU - Kawano, Seiji
AU - Mitsuhashi, Toshiharu
AU - ootsuka, motoyuki
N1 - Publisher Copyright:
© The Author(s) 2025.
PY - 2025/12
Y1 - 2025/12
N2 - Background: Serum C-reactive protein (CRP), leucine-rich alpha-2 glycoprotein (LRG), and fecal calprotectin (Fcal) are non-invasive markers used to assess Crohn’s disease (CD) severity. However, the accuracy of these markers alone is often limited, and most previous reports have evaluated the efficacy of each marker individually. We aimed to improve the diagnostic performance of endoscopic remission (ER) of CD by combining these 3 markers. Methods: We tested the diagnostic ability of various combinations of these 3 markers for endoscopic severity in 230 consecutive patients with CD from September 2014 to July 2023. The modified Simple Endoscopic Score for Crohn’s disease (mSES-CD) was used to determine endoscopic severity. Results: Each of the 3 markers was correlated with mSED-CD (LRG: r = 0.69, CRP: r = 0.60, and Fcal: r = 0.67). A combination of 2 of the 3 markers did not increase the diagnostic accuracy of ER. However, by combining all 3 markers, the diagnostic ability for ER was improved in comparison to the diagnostic ability of the 3 individual markers, assuming that ER was obtained if 2 or 3 markers were negative. The sensitivity, specificity, and accuracy were 89%, 83%, and 86%, respectively. Additionally, we established a 2-step method using Fcal values after evaluating the 2 serum markers. This method was most useful for reducing both the patient burden and costs. Conclusions: The newly established 2-step method allowed for a higher accuracy in the non-invasive diagnosis of ER when the 3 markers were combined.
AB - Background: Serum C-reactive protein (CRP), leucine-rich alpha-2 glycoprotein (LRG), and fecal calprotectin (Fcal) are non-invasive markers used to assess Crohn’s disease (CD) severity. However, the accuracy of these markers alone is often limited, and most previous reports have evaluated the efficacy of each marker individually. We aimed to improve the diagnostic performance of endoscopic remission (ER) of CD by combining these 3 markers. Methods: We tested the diagnostic ability of various combinations of these 3 markers for endoscopic severity in 230 consecutive patients with CD from September 2014 to July 2023. The modified Simple Endoscopic Score for Crohn’s disease (mSES-CD) was used to determine endoscopic severity. Results: Each of the 3 markers was correlated with mSED-CD (LRG: r = 0.69, CRP: r = 0.60, and Fcal: r = 0.67). A combination of 2 of the 3 markers did not increase the diagnostic accuracy of ER. However, by combining all 3 markers, the diagnostic ability for ER was improved in comparison to the diagnostic ability of the 3 individual markers, assuming that ER was obtained if 2 or 3 markers were negative. The sensitivity, specificity, and accuracy were 89%, 83%, and 86%, respectively. Additionally, we established a 2-step method using Fcal values after evaluating the 2 serum markers. This method was most useful for reducing both the patient burden and costs. Conclusions: The newly established 2-step method allowed for a higher accuracy in the non-invasive diagnosis of ER when the 3 markers were combined.
KW - CD, Crohn’s disease
KW - CRP, C-reactive protein
KW - ER, Endoscopic remission
KW - Fcal, Fecal calprotectin
KW - LRG, Leucine-rich alpha- 2 glycoprotein
UR - http://www.scopus.com/inward/record.url?scp=105004833821&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=105004833821&partnerID=8YFLogxK
U2 - 10.1186/s12876-025-03880-5
DO - 10.1186/s12876-025-03880-5
M3 - Article
C2 - 40355822
AN - SCOPUS:105004833821
SN - 1471-230X
VL - 25
JO - BMC Gastroenterology
JF - BMC Gastroenterology
IS - 1
M1 - 364
ER -